Clinical Scores, Biomarkers, and CT Findings in Acute Pulmonary Embolism (PEST)

April 27, 2026 updated by: Esraa Elbadry Elrabie, Sohag University

Comparing Clinical Scores, Biomarkers, and CT Findings in Patients With Acute Pulmonary Embolism Across Different Hospital Departments

This study aims to compare clinical scoring systems, laboratory biomarkers, and computed tomography (CT) findings in patients diagnosed with acute pulmonary embolism in different hospital departments.

The study will include patients diagnosed with acute pulmonary embolism at Sohag University Hospital. Clinical data, laboratory results, and imaging findings will be collected and analyzed to evaluate their diagnostic and prognostic value.

The goal of this research is to identify the most reliable and practical tools for early diagnosis and risk stratification of acute pulmonary embolism, which may help improve patient management and outcomes.

This is an observational study and does not involve any intervention or change in standard patient care.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This study is an observational analytical study designed to evaluate and compare clinical scoring systems, laboratory biomarkers, and computed tomography (CT) findings in patients presenting with acute pulmonary embolism (PE) across different hospital departments at Sohag University Hospital.

Acute pulmonary embolism is a potentially life-threatening condition that requires prompt diagnosis and risk stratification. Various clinical scores (such as Wells score and Geneva score), along with laboratory biomarkers (such as D-dimer and others), and imaging modalities (especially CT pulmonary angiography), are commonly used in the diagnostic and assessment process.

The study aims to assess the diagnostic accuracy and clinical usefulness of these parameters, individually and in combination, in patients with confirmed acute pulmonary embolism.

Data will be collected retrospectively and/or prospectively from patient records and clinical assessments. Variables will include demographic data, clinical presentation, risk factors, laboratory investigations, clinical scoring systems, and radiological findings.

The study will compare these parameters across different hospital departments to determine variations in presentation and diagnostic approaches, as well as to evaluate the best predictive indicators for disease severity and outcomes.

The findings of this study may contribute to improving clinical decision-making, optimizing diagnostic strategies, and enhancing early identification of high-risk patients with acute pulmonary embolism.

This is a non-interventional observational study, and no experimental treatment or intervention will be applied. All data will be handled with confidentiality and in accordance with ethical standards and institutional review board (IRB) approval.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
50

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adult patients with confirmed acute pulmonary embolism admitted to Sohag University Hospital from different departments including Emergency, ICU, Medical, and Surgical wards.

Description

Inclusion Criteria:

  • • Adults aged ≥ 18 years

    • Confirmed acute pulmonary embolism by CTPA

Exclusion Criteria:

  • • Chronic pulmonary embolism

    • Non-diagnostic CTPA
    • Refusal to participate
    • Severe renal impairment precluding contrast-enhanced CT
    • Known hypersensitivity to contrast media

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Acute Pulmonary Embolism Group
This cohort includes patients diagnosed with acute pulmonary embolism at Sohag University Hospital. Participants will be evaluated using clinical scoring systems, laboratory biomarkers, and computed tomography pulmonary angiography (CTPA) findings. No interventions will be applied, and all data will be collected as part of routine clinical care for observational analysis.
Other: No Intervention (Observational Study Data Collection)
This is an observational study with no active intervention. All data are collected from routine clinical care, including clinical scoring systems, laboratory biomarkers, and computed tomography pulmonary angiography (CTPA) findings in patients with acute pulmonary embolism.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Number of Participants with In-Hospital All-Cause Mortality
Time Frame: Up to 30 days
All-cause mortality among adult patients with confirmed acute pulmonary embolism, defined as death from any cause occurring during hospitalization. The outcome will be assessed as the number of participants who die before hospital discharge.
Up to 30 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Sohag University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 1, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 1, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 4, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 27, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 5, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 5, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 27, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • PE-Score-CT-2025

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Pulmonary Embolism

Clinical Trials on No Intervention (Observational Study Data Collection)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings